[Kovaltry® for the replacement therapy in patients with Hemophilia A]

Daniela Paola Roggeri, Alessio Colombo, Alessandro Roggeri

DOI: https://doi.org/10.7175/fe.v17i2.1250

Abstract

[Article in Italian]

Keywords

Hemophilia A; Recombinant factor VIII; Replacement therapy

Full Text

HTML PDF

References

  • Istituto Superiore di Sanità. Registro Nazionale Coagulopatie Congenite. Rapporto 2013.F. Abbonizio, A. Giampaolo, R. Arcieri, H. J. Hassan e Associazione Italiana Centri Emofilia (AICE) 2015, iii, 72 p. Rapporti ISTISAN 15/14
  • Committee for medicinal products for human use (CHMP). Guideline on the clinical investigation of recombinant and 4 human plasma-derived factor VIII products. EMA/CHMP/BPWP/144533/2009 rev. 1. 21 maggio 2015
  • Rocino A, Coppola A, Franchini M, et al. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfusion 2014; 12: 575-98; http://dx.doi.org/10.2450/2014.0223-14
  • Strawczynski H, Stachewitsch A, Morgenstern G, et al. Delivery of care to hemophilic children: home care versus hospitalization. Pediatrics 1975; 51: 986-91
  • Kavakli K, Yang R, Rusen L, et al. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost 2015; 13: 360-9; http://dx.doi.org/10.1111/jth.12828
  • Saxena K, Lalezari S, Oldenburg J, et al. Pharmacokinetics, efficacy, and safety of BAY 81-8973, a full-length plasma-protein-free recombinant factor VIII product: results from the LEOPOLD trial. J Thromb Haemost 2013; 11: 928
  • Ljung R, Kenet G, Mancuso ME, Kaleva V, Rusen L, Tseneklidou-Stoeter D. , Michaels L.A., Shah A, Hong W, BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe hemophilia A: results of the LEOPOLD Kids Trial. Haemophilia 2016; 22: 354-60; http://dx.doi.org/10.1111/hae.12866
  • Advate® – Riassunto delle Caratteristiche di Prodotto
  • Helixate Nexgen® – Riassunto delle Caratteristiche di Prodotto
  • Kogenate Bayer® – Riassunto delle Caratteristiche di Prodotto
  • Recombinate® – Riassunto delle Caratteristiche di Prodotto
  • Refacto AF® – Riassunto delle Caratteristiche di Prodotto
  • NovoEight® – Riassunto delle Caratteristiche di Prodotto
  • Nuwiq® – Riassunto delle Caratteristiche di Prodotto
  • Kovaltry® – Riassunto delle Caratteristiche di Prodotto

Statistics

Abstract: 1569 views
HTML: 1103 views
PDF: 650 views

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.